Effects of Vaccination on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study

Article information

Tuberc Respir Dis. 2025;88(3):526-534

Publication date (electronic) : 2025 February 27

doi : https://doi.org/10.4046/trd.2024.0182

, Min Ji Kim ⁴^,⁵, Min Gu Kang ⁴^,⁵, Jong Seung Kim ⁴^,⁵^,⁶, Jong Geol Jang ⁷, Youlim Kim ⁸, Hyeon-Kyoung Koo ⁹, Chin Kook Rhee ¹⁰, Kyung Hoon Min ², Yong Il Hwang ¹¹, Deog Kyeom Kim ¹², Yong Bum Park^,¹³

, Ji-Yong Moon^,⁸

, on behalf of the Korean COPD Study Group

¹Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Gyeongju, Republic of Korea

²Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea

³Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Republic of Korea

⁴Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Republic of Korea

⁵Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea

⁶Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Medical School, Jeonju, Republic of Korea

⁷Division of Pulmonology and Allergy, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Republic of Korea

⁸Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea

⁹Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea

¹⁰Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

¹¹Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea

¹²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea

¹³Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Republic of Korea

Address for correspondence Yong Bum Park Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, 150 Seongan-ro, Gangdong-gu, Seoul 05355, Republic of Korea Phone 82-2-2225-2754 Fax 82-2-2224-2569 E-mail bfspark2@gmail.com

Address for correspondence Ji-Yong Moon Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdongro, Gwangjin-gu, Seoul 05030, Republic of Korea Phone 82-2-2030-7524 Fax 82-2-2030-7748 E-mail respiry@gmail.com

*These authors contributed equally to the manuscript as first author.

Received 2024 December 5; Revised 2025 January 31; Accepted 2025 February 24.

Abstract

Background

Coronavirus disease 2019 (COVID-19) vaccination may offer benefits for patients with chronic obstructive pulmonary disease (COPD). However, the evidence on whether the vaccination decreases the frequency of acute exacerbation of COPD (AECOPD) is limited.

Methods

This study enrolled 41,606 individuals diagnosed with COPD using the Korean National Health Insurance System-severe acute respiratory syndrome coronavirus 2 (NHIS SARS-CoV-2) database between 2020 and 2021. A cohort of 3,602 individuals was analyzed through 1:1 propensity score matching of vaccinated and unvaccinated groups. The risk of AECOPD was evaluated using a Cox proportional hazards regression analysis. A post hoc analysis examined the impact of COVID-19 on AECOPD in vaccinated and unvaccinated groups among infected and uninfected subgroups.

Results

Throughout the study, the exacerbation rate was lower in the vaccinated group (1,683/10,000 person-years) compared to the unvaccinated group (3,410/10,000 personyears). The Cox proportional hazards model showed a significantly decreased risk of AECOPD in vaccinated individuals relative to unvaccinated individuals (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41 to 0.72). post hoc analysis revealed that COVID-19 was associated with a higher risk of AECOPD in unvaccinated individuals (adjusted HR, 2.06; 95% CI, 1.28 to 3.33), while in vaccinated individuals, the risk did not significantly differ between those infected and not infected with COVID-19 (adjusted HR, 1.35; 95% CI, 0.42 to 4.36).

Conclusion

COVID-19 vaccination appears to decrease the risk of AECOPD among individuals with COPD.

Keywords: Chronic Obstructive Pulmonary Disease; Respiratory Disease; Vaccination; COVID-19; Exacerbation; Vaccination Recommendation

Introduction

The importance of vaccines in ending the global coronavirus disease 2019 (COVID-19) pandemic is immense [1]. Vaccines have markedly decreased the risk of infection and the progression to severe COVID-19, thus preventing severe outcomes, including mortality [2]. Therefore, vaccination is strongly advised for individuals at high risk of severe COVID-19, such as the elderly and those with pre-existing health conditions [3]. Among these conditions, COVID-19 vaccination is particularly emphasized for individuals with various chronic respiratory diseases [4].

Chronic obstructive pulmonary disease (COPD) ranks as the third leading cause of death worldwide and incurs a substantial economic burden [5,6]. COPD constitutes a significant chronic respiratory condition for which COVID-19 vaccination is strongly advised [7]. Current evidence presents mixed findings concerning the effects of COVID-19 vaccination on the acute exacerbation of COPD (AECOPD). In one study, fully vaccinated COPD patients exhibited a higher rate of exacerbations compared with those not fully vaccinated (70.5% vs. 55.3%) [8]. Conversely, another study reported significantly fewer severe and moderate COPD exacerbations in vaccinated patients compared with unvaccinated ones during a 6-month period post-vaccination [9]. Additionally, evidence suggesting worse COVID-19 outcomes in COPD patients complicates the understanding of associations among COVID-19 vaccination, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [10], and AECOPD. As the COVID-19 pandemic transitions to an endemic phase, it is essential to understand these relationships.

To explore these complex associations, this study aimed to evaluate the risk of AECOPD based on COVID-19 vaccination status and COVID-19 status in individuals with COPD.

Materials and Methods

1. Data source

We conducted a retrospective cohort study using data from the Korean National Health Insurance System (NHIS) [11-13]. The NHIS, a government-operated universal insurance program, covers approximately 97% of the population, encompassing around 50 million individuals. The NHIS database has been extensively utilized in numerous epidemiological studies associated with COVID-19 and its subsequent complications [14-18].

During the COVID-19 pandemic in 2020 and 2021, the Korean government actively promoted testing by subsidizing diagnostic procedures for those presenting symptoms indicative of the virus. It also provided financial aid for treating individuals diagnosed with COVID-19 (NHIS-2022-1-623). The NHIS-SARS-CoV-2 database, which includes test results for all individuals tested for the virus, was established based on these data.

2. Study population

The inclusion criteria identified individuals over the age of 20 with previously diagnosed COPD before February 26, 2021, and individuals who contracted COVID-19 prior to March 31, 2022. Exclusion criteria were lack of available health examination data, vaccination following COVID-19 diagnosis, diagnosis of COPD after COVID-19 infection, and death before the index date or December 31, 2021. We excluded individuals who died before December 31, 2021, to prevent the assignment of index dates to those who had not been vaccinated.

COPD was defined by a minimum of two prescriptions in 1 year for medicines specific to COPD, under the International Classification of Diseases 10th Revision (ICD-10) codes J43.1, J43.2, J43.8, J43.9, or J44. This included several types of bronchodilators, as detailed in our previous studies [19]. The index date was defined as the vaccination date for vaccinated subjects, and a corresponding matched date for unvaccinated subjects.

In the COVID-19 vaccination-COPD cohort, we performed propensity score (PS) matching employing a 1:1 ratio between vaccinated and unvaccinated individuals, considering variables such as age, sex, body mass index (BMI), smoking status, alcohol consumption, economic status, residential area, regular physical activity, one or more severe exacerbations in the previous year, and comorbid conditions including hypertension, diabetes, dyslipidemia, chronic kidney disease (CKD), and asthma (Figure 1).

Fig. 1.

Flow chart of the study population. NHIS-SARS-CoV-2: National Health Insurance System-Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19: coronavirus disease 2019; COPD: chronic obstructive pulmonary disease; PS: propensity score.

3. Exposure: COVID-19 vaccination

The exposure for this study was vaccination against COVID-19, which began in South Korea on February 26, 2021. By October 23, 2021, over 70% of individuals had received at least two doses of the COVID-19 vaccine [20].

4. AECOPD

AECOPD was identified by either emergency room visits or hospitalizations for COPD-related ICD-10 codes along with the concurrent prescription of systemic steroids [21]. Study participants were monitored from the index date until the first exacerbation occurrence, censoring, or the conclusion of the 90-day follow-up period post-vaccination.

5. Post hoc analysis

We conducted a post hoc analysis to assess the impact of COVID-19 on AECOPD among both vaccinated and unvaccinated groups. The exposure considered in this analysis was SARS-CoV-2 infection, characterized by a COVID-19 diagnosis confirmed through reverse transcription polymerase chain reaction tests on nasal or pharyngeal swabs, as identified by the ICD-10 code (U07.1) [16].

6. Covariates

BMI was calculated by dividing weight by the square of height (kg/m²). BMI was categorized into five groups according to recommendations for Asians: underweight (<18.5 kg/m²); normal weight (18.5–22.9 kg/m²); overweight (23.0–24.9 kg/m²); obese (25–29.9 kg/m²); and highly obese (≥30 kg/m²) [22,23]. Smoking status was categorized into current smokers, former smokers, and never smokers [24]. Economic status was defined based on personal income, with high income representing the top 30%, low income encompassing the bottom 30% and recipients of medical aid, and middle income covering the remaining population. Regular physical activity was defined as moderate activity for more than 30 minutes on most days of the week or vigorous activity for more than 20 minutes on more than 3 days per week. Alcohol consumption was categorized into four levels: none, 1–2 times per week, 3–4 times per week, and almost daily [25]. A history of AECOPD was defined as either an emergency room visit or hospitalization involving the use of systemic steroids and associated with ICD-10 codes for COPD within the past year. Asthma was identified using ICD-10 codes J45–J46 and the prescription of asthma-related medications, which include systemic steroids, bronchodilators, leukotriene receptor antagonists, and xanthine derivatives [14,16]. Other comorbidities, such as hypertension, diabetes mellitus, dyslipidemia, and CKD, were identified using corresponding ICD-10 codes [13,26-33].

7. Statistical analysis

Categorical and continuous variables were respectively presented as numbers (percentages) and median (interquartile range). The chi-square test was utilized to compare categorical variables across study groups. The incidence of exacerbation was reported as the number of exacerbation events per 10,000 person-years (PY). Kaplan-Meier curves were employed to visualize the incidence of AECOPD by vaccination status, with statistical significance determined using the logrank test. Initially, Cox proportional hazards regression models evaluated the risk of AECOPD without adjustment, as all variables demonstrated a standardized mean difference (SMD) <0.25 [34]. However, in the post hoc analysis, due to some variables not satisfying the SMD < 0.25 criterion, additional adjustments were made, including factors such as age, sex, BMI, smoking status, alcohol consumption, economic status, residential area, regular physical activity, one or more severe exacerbations in the previous year, and comorbidities such as hypertension, diabetes, dyslipidemia, CKD, and asthma. A two-sided p<0.05 was considered statistically significant. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

8. Ethics approval

The study protocol was approved by the Institutional Review Board of Hanyang University Hospital (No. HYUH 2023-11-049). The requirement for informed consent was waived due to the anonymization of all patient records prior to their use.

9. Data sharing statement

The data that support the findings of this study are available from the Korea NHIS but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Korea NHIS.

Results

1. Baseline characteristics

The selection process for individuals included in the analysis is depicted in Figure 1. Out of the 4,758,546 individuals in the NHIS-SARS-CoV-2 database, 4,713,157 were excluded due to the absence of health examination data, 810 were vaccinated after a COVID-19 infection, 71 were diagnosed with COPD post-COVID-19 infection, and 4,004 died before the index date or December 31, 2021. Consequently, 40,504 individuals with COPD were enrolled in the COVID-19 vaccination-COPD cohort. Of these, 3,602 were selected following 1:1 PS matching.

Baseline characteristics of the study population are detailed in Table 1. The majority of individuals were male (62.9%) and aged between 60 and 79 years (63.1%). No significant differences in baseline characteristics were observed between vaccinated and unvaccinated individuals.

Table 1.

Baseline characteristics of the study population (step 1)

2. Risk of AECOPD

Throughout the study period, the incidence of AECOPD was notably lower in vaccinated individuals (1,683/10,000 PY) compared to unvaccinated individuals (3,410/10,000 PY). As indicated in Table 2, the risk of AECOPD was significantly decreased in vaccinated compared to unvaccinated individuals (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41 to 0.72). This finding was corroborated by cumulative incidence plots (log-rank p<0.001) (Figure 2).

Table 2.

Risk of AECOPD based on COVID-19 vaccination status

Fig. 2.

Kaplan-Meier curves for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) based on coronavirus disease 2019 (COVID-19) vaccination status.

3. Post hoc analysis

The results of the post hoc analysis are detailed in Table 3. The post hoc analysis revealed a COVID-19 diagnosis rate of 3.9% among vaccinated individuals and 8.0% among unvaccinated individuals. Despite the general similarity in the clinical characteristics of infected and uninfected individuals, residents of metropolitan cities exhibited a higher susceptibility to COVID-19, irrespective of their vaccination status (Supplementary Table S1).

Table 3.

Post hoc analysis for risk of AECOPD based on COVID-19 status

COVID-19 was associated with an elevated risk of AECOPD in unvaccinated individuals, even after adjustments were made (adjusted HR, 2.06; 95% CI, 1.28 to 3.33). Conversely, the risk of AECOPD in vaccinated individuals was not significantly different between those with and without COVID-19 infection (adjusted HR, 1.35; 95% CI, 0.42 to 4.36).

Discussion

In this nationwide cohort study, vaccinated individuals with COPD had a significantly lower risk of AECOPD compared to unvaccinated individuals. COVID-19 increased the risk of AECOPD in the unvaccinated group, whereas vaccinated individuals had a similar risk of exacerbation regardless of COVID-19 status. These findings underscore the protective benefits of COVID-19 vaccination in individuals with COPD.

Individuals with COPD who experience exacerbations are at increased risk of subsequent AECOPD events [35,36]. Additionally, recurrent exacerbations frequently lead to hospital readmissions following an AECOPD episode [37]. A recent systematic review and meta-analysis reported readmission rates of 11% at 30 days, 17% at 90 days, and 37% at 1 year [38]. These data highlight the critical need for interventions to mitigate the risk of recurrent exacerbations. Proposed measures include pulmonary rehabilitation and nutritional supplementation after an AECOPD event [39,40], yet proactive strategies to prevent AECOPD are still limited.

The role of respiratory infections in triggering AECOPD is well established [41]. Particularly, viral infections influence the lung microbiota and host immune responses, thereby increasing the risk of AECOPD [42,43]. Consequently, vaccination against respiratory infections could offer protection against AECOPD. Several studies support this hypothesis, reporting that influenza and pneumococcal vaccines reduce the risk of AECOPD [44,45]. Similarly, vaccination against COVID-19 might help prevent recurrent exacerbations. However, the available information on this matter is limited [46], and conflicting outcomes have been documented. While one study identified an increased risk of AECOPD following COVID-19 vaccination [8], another indicated that the vaccine may protect against AECOPD [9]. The reasons for these conflicting results are not fully understood; however, it is theorized that a complex interaction among COVID-19 vaccination, susceptibility to COVID-19, and subsequent AECOPD in individuals with COPD could explain these findings.

This study observed a decreased incidence of AECOPD in vaccinated individuals, emphasizing the potential benefits of COVID-19 vaccination in mitigating exacerbations among individuals with COPD. AECOPD is associated with healthcare utilization increase, accelerated decline in lung function, and diminished quality of life [36]. Given the substantial morbidity and healthcare burden linked to AECOPD, it is imperative for clinicians to recognize COVID-19 vaccination as an essential component of preventive care strategies for these patients. Further research is needed to clarify the specific mechanisms behind the observed benefits and to assess the potential long-term effects of vaccination on COPD outcomes.

A plausible explanation for these findings is that vaccination decreases the risk of symptomatic COVID-19 infection, hospitalization, and severe illness in individuals with COPD. This is corroborated by our post hoc analysis, which indicated that unvaccinated individuals were more likely to contract COVID-19 and also faced an elevated risk of AECOPD. Although this study is observational and cannot establish causality, these results offer indirect evidence that vaccination may decrease the future risk of AECOPD in individuals with COPD.

There are limitations to our study. First, the diagnosis of COPD was based on ICD-10 codes, which may lead to under- or over-diagnosis. Second, potential confounding factors affecting the risk of AECOPD, such as etiology, pulmonary function, and other laboratory findings, could not be controlled due to the absence of this data in the dataset [47,48]. Third, most of the study period occurred before the emergence of the Omicron variant of COVID-19, and during this time, social restrictions were relatively stringent. Certain unaccounted factors, including social distancing, may influence the study outcomes [49]. Fourth, as this study was conducted in a single Asian country, caution should be exercised when generalizing the findings.

In conclusion, COVID-19 vaccination may decrease the risk of AECOPD in individuals with COPD.

Notes

Authors’ Contributions

Conceptualization: all authors. Methodology: Lee H, Moon JY. Formal analysis: Kim SH, Lee H, Kim MJ, Kim JS, Moon JY. Data curation: all authors. Funding acquisition: Moon JY. Project administration: Kim JS, Moon JY. Visualization: Kim SH, Kim MJ. Software: Kim MJ, Kang MG. Validation: Park YB, Moon JY. Investigation: Kim SH, Lee H. Writing - original draft preparation: Kim SH, Lee H. Writing - review and editing: Kim SH, Lee H. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Funding

This research was supported by the Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) and the Korea National Institute of Health research project.

Supplementary Material

Supplementary material can be found in the journal homepage (http://www.e-trd.org).

Supplementary Table S1.

Clinical characteristics of vaccinated and unvaccinated individuals according to the infection status.

trd-2024-0182-Supplementary-Table-S1.pdf

References

1. Krammer F. The role of vaccines in the COVID-19 pandemic: what have we learned? Semin Immunopathol 2024;45:451–68.

2. de Gier B, van Asten L, Boere TM, van Roon A, van Roekel C, Pijpers J, et al. Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022. Vaccine 2023;41:4488–96.

3. Centers for Disease Control and Prevention (CDC). Recommendations for the use of COVID-19 vaccines [Internet]. Atlanta: CDC; 2025 [cited 2025 Mar 31]. Available from: https://www.cdc.gov/vaccines/covid-19/clinicalconsiderations/interim-considerations-us.html.

4. Mallah N, Urbieta AD, Rivero-Calle I, Gonzalez-Barcala FJ, Bigoni T, Papi A, et al. New vaccines for chronic respiratory patients. Arch Bronconeumol 2024;60:565–75.

5. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet 2022;399:2227–42.

6. Pham HQ, Pham KH, Ha GH, Pham TT, Nguyen HT, Nguyen TH, et al. Economic burden of chronic obstructive pulmonary disease: a systematic review. Tuberc Respir Dis (Seoul) 2024;87:234–51.

7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2024 report [Internet]. Deer Park: GOLD; 2024 [cited 2025 Mar 31]. Available from: http://goldcopd.org/2024-gold-report.

8. Sahin Ozdemirel T, Zenbilli E, Ensarioglu K, Hosgun D, Balkay Babaev B, Ak Ayaroglu M, et al. Evaluation of the effect of COVID-19 vaccination on exacerbations of chronic obstructive pulmonary disease: a single-center study. Cureus 2022;14e32751.

9. Fekete M, Horvath A, Santa B, Tomisa G, Szollosi G, Ungvari Z, et al. COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease: a cross-sectional study in Hungary. Vaccine 2023;41:193–200.

10. Kim Y, Lee H, Lee SK, Yang B, Choi H, Park DW, et al. Chronic obstructive pulmonary disease is associated with a more symptomatic burden and severe presentation of COVID-19: a Korean national COVID-19 cohort study. Tohoku J Exp Med 2022;256:209–14.

11. Kim SH, Kim Y. Big data research on severe asthma. Tuberc Respir Dis (Seoul) 2024;87:213–20.

12. Shin DW, Cho J, Park JH, Cho B. National general health screening program in Korea: history, current status, and future direction. Precis Future Med 2022;6:9–31.

13. Choi H, Park HY, Han K, Yoo J, Shin SH, Yang B, et al. Non-cystic fibrosis bronchiectasis increases the risk of lung cancer independent of smoking status. Ann Am Thorac Soc 2022;19:1551–60.

14. Lee H, Kim BG, Jeong CY, Park DW, Park TS, Moon JY, et al. Long-term impacts of COVID-19 on severe exacerbation and mortality in adult asthma: a nationwide population-based cohort study. J Allergy Clin Immunol Pract 2024;12:1783–93.e4.

15. Lee H, Choi H, Yang B, Lee SK, Park TS, Park DW, et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021;58:2004125.

16. Kim BG, Lee H, Yeom SW, Jeong CY, Park DW, Park TS, et al. Increased risk of new-onset asthma after COVID-19: a nationwide population-based cohort study. J Allergy Clin Immunol Pract 2024;12:120–32.e5.

17. Kim SH, Kim JS, Kim MJ, Jin S, Kim BG, Moon SM, et al. Exacerbation and mortality risk in individuals with bronchiectasis post-COVID-19 recovery. ERJ Open Res 2025;2025:00866-2024.

18. Kim BG, Lee H, Jeong CY, Yeom SW, Park DW, Park TS, et al. Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: a nationwide population-based cohort study. Front Public Health 2024;11:1295457.

19. Kim T, Choi H, Kim SH, Yang B, Han K, Jung JH, et al. Increased risk of incident chronic obstructive pulmonary disease and related hospitalizations in tuberculosis survivors: a population-based matched cohort study. J Korean Med Sci 2024;39e105.

20. Korea Disease Control and Prevention Agency. 70% of the population has completed their second COVID-19 vaccination! [Internet]. Cheongju: KDCA; 2021 [cited 2025 Mar 31]. Available from: https://www.kdca.go.kr/gallery.es?mid=a20503030300&bid=0004&b_list=9&act=view&list_no=145359&nPage=15&vlist_no_npage=15&keyField=&keyWord=&orderby=.

21. Kim Y, Kim SH, Rhee CK, Lee JS, Lee CY, Kim DK, et al. Air trapping and the risk of COPD exacerbation: analysis from prospective KOCOSS cohort. Front Med (Lausanne) 2022;9:835069.

22. Yang B, Han K, Kim SH, Lee DH, Park SH, Yoo JE, et al. Being underweight increases the risk of non-cystic fibrosis bronchiectasis in the young population: a nationwide population-based study. Nutrients 2021;13:3206.

23. Cho SH, Lee H, Kwon H, Shin DW, Joh HK, Han K, et al. Association of underweight status with the risk of tuberculosis: a nationwide population-based cohort study. Sci Rep 2022;12:16207.

24. Yang B, Han K, Kim B, Kang HK, Kim JS, Kim EG, et al. Association between smoking status and incident non-cystic fibrosis bronchiectasis in young adults: a nationwide population-based study. J Pers Med 2022;12:691.

25. Yoo JE, Kim D, Choi H, Kang YA, Han K, Lee H, et al. Anemia, sarcopenia, physical activity, and the risk of tuberculosis in the older population: a nationwide cohort study. Ther Adv Chronic Dis 2021;12:20406223211015959.

26. Choi H, Kim SH, Han K, Park TS, Park DW, Moon JY, et al. Association between exercise and risk of cardiovascular diseases in patients with non-cystic fibrosis bronchiectasis. Respir Res 2022;23:288.

27. Yoo JE, Kim D, Han K, Rhee SY, Shin DW, Lee H. Diabetes status and association with risk of tuberculosis among Korean adults. JAMA Netw Open 2021;4e2126099.

28. Yang B, Kim T, Ryu J, Park HY, Hwangbo B, Kong SY, et al. Increased incidence and associated risk factors of aspergillosis in patients with bronchiectasis. J Pers Med 2021;11:422.

29. Choi H, Lee H, Ryu J, Chung SJ, Park DW, Sohn JW, et al. Bronchiectasis and increased mortality in patients with corticosteroid-dependent severe asthma: a nationwide population study. Ther Adv Respir Dis 2020;14:1753466620963030.

30. Jo YS, Han K, Kim D, Yoo JE, Kim Y, Yang B, et al. Relationship between total cholesterol level and tuberculosis risk in a nationwide longitudinal cohort. Sci Rep 2021;11:16254.

31. Lee HR, Yoo JE, Choi H, Han K, Jung JH, Park J, et al. Tuberculosis and risk of ischemic stroke: a nationwide cohort study. Stroke 2022;53:3401–9.

32. Kim Y, Han K, Yoo J, Kang HK, Park TS, Park DW, et al. Risk factors of incident lung cancer in patients with non-cystic fibrosis bronchiectasis: a Korean population-based study. Cancers (Basel) 2022;14:2604.

33. Yeo Y, Lee H, Ryu J, Chung SJ, Park TS, Park DW, et al. Additive effects of coexisting respiratory comorbidities on overall or respiratory mortality in patients with asthma: a national cohort study. Sci Rep 2022;12:8105.

34. Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcome Res Methodol 2001;2:169–88.

35. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128–38.

36. Jo YS. Long-term outcome of chronic obstructive pulmonary disease: a review. Tuberc Respir Dis (Seoul) 2022;85:289–301.

37. Echevarria C, Steer J, Heslop-Marshall K, Stenton SC, Hickey PM, Hughes R, et al. The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPD. Thorax 2017;72:686–93.

38. Ruan H, Zhang H, Wang J, Zhao H, Han W, Li J. Readmission rate for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med 2023;206:107090.

39. Stefan MS, Pekow PS, Priya A, ZuWallack R, Spitzer KA, Lagu TC, et al. Association between initiation of pulmonary rehabilitation and rehospitalizations in patients hospitalized with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2021;204:1015–23.

40. Beijers RJ, Steiner MC, Schols AM. The role of diet and nutrition in the management of COPD. Eur Respir Rev 2023;32:230003.

41. Lee HW, Sim YS, Jung JY, Seo H, Park JW, Min KH, et al. A multicenter study to identify the respiratory pathogens associated with exacerbation of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul) 2022;85:37–46.

42. Merenstein C, Bushman FD, Collman RG. Alterations in the respiratory tract microbiome in COVID-19: current observations and potential significance. Microbiome 2022;10:165.

43. Sin DD. Chronic obstructive pulmonary disease and the airway microbiome: what respirologists need to know. Tuberc Respir Dis (Seoul) 2023;86:166–75.

44. Fekete M, Pako J, Nemeth AN, Tarantini S, Varga JT. Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations. J Thorac Dis 2020;12:4233–42.

45. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018;6:CD002733.

46. Simon S, Joean O, Welte T, Rademacher J. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus. Eur Respir Rev 2023;32:230034.

47. Gu KM, Jung JW, Kang MJ, Kim DK, Choi H, Cho YJ, et al. Eosinophilia is a favorable marker for pneumonia in chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul) 2024;87:465–72.

48. Kim SH, Moon JY, Min KH, Lee H. Proposed etiotypes for chronic obstructive pulmonary disease: controversial issues. Tuberc Respir Dis (Seoul) 2024;87:221–33.

49. Ko Y, Ngai ZN, Koh RY, Chye SM. Association among lifestyle and risk factors with SARS-CoV-2 infection. Tuberc Respir Dis (Seoul) 2023;86:102–10.

Article information Continued

It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

Characteristic	Vaccinated (n=1,801)	Unvaccinated (n=1,801)	SMD
Age, yr			0.209
20–49	207 (11.5)	128 (7.1)
50–59	161 (8.9)	188 (10.4)
60–69	552 (30.6)	591 (32.8)
70–79	520 (28.9)	611 (33.9)
≥80	361 (20.0)	283 (15.7)
Male sex	1,101 (61.1)	1,163 (64.6)	0.071
BMI			0.198
Low (<18.5 kg/m²)	195 (10.8)	114 (6.3)
Normal (18.5–22.9 kg/m²)	689 (38.3)	653 (36.3)
Overweight (23.0–24.9 kg/m²)	340 (18.9)	383 (21.3)
Obese (25.0–29.9 kg/m²)	456 (25.3)	549 (30.5)
Highly obese (≥30 kg/m²)	121 (6.7)	102 (5.7)
Smoking status			0.037
Never smoker	974 (54.1)	943 (52.4)
Former smoker	422 (23.4)	447 (24.8)
Current smoker	405 (22.5)	411 (22.8)
Alcohol consumption
None	1,450 (80.5)	1,370 (76.1)	0.112
1–2 times	195 (10.8)	233 (12.9)
3–4 times	86 (4.8)	117 (6.5)
Almost every day	70 (3.9)	81 (4.5)
Economic status			0.090
Low	532 (29.5)	468 (26.0)
Middle	775 (43.0)	781 (43.4)
High	494 (27.4)	552 (30.6)
Residential area
Rural areas	278 (15.4)	284 (15.8)	0.016
Mid-size and small cities	496 (27.5)	504 (28.0)
Metropolitan cities	1,027 (57.0)	1,013 (56.2)
Regular physical activity	406 (22.5)	439 (24.4)	0.043
One or more severe exacerbations in the previous year	456 (25.3)	350 (19.4)	0.142
Comorbidities
Hypertension	687 (38.1)	739 (41.0)	0.059
Diabetes mellitus	405 (22.5)	424 (23.5)	0.025
CKD	78 (4.3)	90 (5.0)	0.052
Dyslipidemia	235 (13.0)	278 (15.4)	0.068
Asthma	752 (41.8)	732 (40.6)	0.023

COVID-19 vaccination	Number	Number of AECOPD	AECOPD, /10,000 population	HR (95% CI)
No	1,801	144	3,410	Reference
Yes	1,801	73	1,683	0.55 (0.41–0.72)

Population	COVID-19	Number	Number of AECOPD	AECOPD, /10,000 population	HR (95% CI)	Adjusted HR (95% CI)
Vaccinated	No	1,731	70	1,679	Reference	Reference
	Yes	70	3	1,781	1.06 (0.33–3.36)	1.35 (0.42–4.36)
Unvaccinated	No	1,655	124	3,190	Reference	Reference
	Yes	146	20	5,966	1.86 (1.16–2.98)	2.06 (1.28–3.33)